The Smart Investor
    Facebook Instagram
    Sunday, July 26
    Facebook Instagram LinkedIn
    The Smart Investor
    • Home
    • About
      • About Us
      • Careers
    • Smart Investing
      • Getting Started
      • Investing Strategy
      • Smart Analysis
      • Smart Reads
    • US Stocks
    • Special Free Reports!
    • As Featured on BT
    • Our Services
      • Our Services
      • Subscribe now!
    • Login
    • Cart
    The Smart Investor
    Home»Dividend Stocks»Raffles Medical Group’s 2023 Net Profit Tumbles 37% Year on Year: 5 Highlights from the Integrated Healthcare Player’s Latest Earnings
    Dividend Stocks

    Raffles Medical Group’s 2023 Net Profit Tumbles 37% Year on Year: 5 Highlights from the Integrated Healthcare Player’s Latest Earnings

    The integrated healthcare player sees better days ahead with its latest Vietnam hospital acquisition.
    Royston Y.By Royston Y.February 27, 20244 Mins Read
    Facebook Twitter LinkedIn Email WhatsApp
    Raffles Hospital
    Image credit: rafflesmedicalgroup.com
    Share
    Facebook Twitter LinkedIn Email WhatsApp

    Raffles Medical Group (SGX: BSL), or RMG, is next on the list to release its 2023 earnings.

    The integrated healthcare player delivered a downbeat set of earnings as revenue from COVID-19 procedures and tests tapered off.

    The group’s new insurance arm also acted as a drag on the group’s net profit.

    Despite the weaker numbers, there were several bright spots for RMG with patient numbers rising and its China hospitals being recognised for their excellence.

    Here are five highlights from RMG’s latest financial statements that investors should know about.

    1. Weaker net profit offset by steady free cash flow generation

    Revenue for 2023 fell by 14.1% year on year to S$706.9 million as revenue for the Healthcare Services division fell sharply because of the cessation of COVID-19 activities.

    Higher insurance expenses pushed RMG’s operating profit down nearly 41% year on year to S$115.8 million.

    Aided by a year-on-year increase in finance income, the healthcare player’s net profit tumbled by 37.1% year on year to S$90.2 million.

    RMG’s balance sheet remained robust with S$343.6 million of cash along with S$70.6 million of loans.

    Despite the sharp fall in net profit, the group’s free cash flow generation remained robust.

    2023 saw a positive free cash flow of S$167.4 million, just 2.1% lower than the free cash flow of S$170.9 million churned out in 2022.

    2. Addressing evolving patient needs in Singapore

    RMG continued to see steady growth in the number of patients with patients’ needs also evolving.

    Its Healthcare Services revenue fell by 36.3% year on year to S$283.4 million due to the aforementioned cessation of COVID-19-related revenue.

    Segment profit before tax (PBT) plunged by 59.4% year on year to S$67.3 million.

    Segment margin declined from 37.2% to 23.8%.

    RMG will take in more specialists, physicians, and nurses to offer a wider range of healthcare services across its operations while fine-tuning its capacity management strategies.

    In particular, the group is looking to enhance its teleconsultation platform to handle patient growth and deliver a better experience.

    RMG is also working with Singapore’s Ministry of Health to operate transitional care facilities with 176 additional beds dedicated to this programme.

    These additions will help to improve the scale of the operation.

    3. Gestational losses for China hospitals

    RMG’s Hospitals division performed better.

    Segment revenue increased by 4.5% year on year to S$330.6 million.

    Segment PBT shot up 52.2% year on year to S$32.6 million, giving the division a PBT margin of 9.9%, up from 6.8% a year back.

    RMG’s Chongqing and Shanghai hospitals are seeing growing patient numbers but are still in their development phase.

    Therefore, both continued to incur gestational losses.

    The healthcare group plans to consolidate its three existing hospitals in China.

    Management warned of a possible economic slowdown but believes that high-end healthcare demand should continue to grow in the region.

    To this end, RMG entered a strategic partnership to manage the American International Hospital (AIH) in Ho Chi Minh City, Vietnam.

    4. Higher loss ratio for its insurance division

    RMG’s health insurance arm, Raffles Health Insurance (RHI), saw revenue increase by 25.6% year on year to S$144.5 million.

    However, the division incurred a loss before tax of S$7 million compared to a small profit of S$531,000 last year because of a higher loss ratio.

    The loss ratio is defined as the losses an insurer incurs from paying out claims as a proportion of the premiums it earns.

    5. A reduction in the final dividend

    In line with the weaker results for 2023, RMG slashed its final dividend from S$0.038 last year to S$0.024.

    The healthcare player’s shares offer a 2.3% dividend yield based on the share price of S$1.05 as of 23 February 2024.

    Get Smart: A sanguine outlook for 2024

    Loo Choon Yong, Executive Chairman of RMG, offered a sanguine outlook for this year.

    He acknowledged that there were geopolitical and macroeconomic headwinds but believes that there is a growing demand for quality healthcare in Singapore and the region.

    RMG is in a good position to deliver this level of service as it can provide seamless care as a team.

    The group expects to remain profitable for 2024.

    Want to protect your child’s money from inflation? Transform your child’s ‘piggy bank’ into a ‘golden goose’ that keeps giving even until they have grandchildren. Our latest FREE report shows you a stress-free method and 3 superstar stocks that could protect your child’s money from inflation. Click HERE to get a copy of our latest guide.

    Disclosure: Royston Yang owns shares of Raffles Medical Group.

    Yahoo
    Share. Facebook Twitter LinkedIn Email WhatsApp

    Related Posts

    The Smart Investor Smart Reads Pic 8

    Smart Reads of the Week: Passive Income, Singapore Dividend Stocks, and REIT Growth Opportunities

    July 26, 2026

    Top Stock Market Highlights of the Week: Metro Holdings, Singapore Exchange, Mi Technovation and Singapore’s Inflation

    July 25, 2026
    bull market, stock market up

    Get Smart: The Biggest Risk When The STI is at a Record High

    July 24, 2026
    Facebook Instagram LinkedIn Telegram
    • Careers
    • Disclaimer & Privacy Policy
    • Advertising & Media Enquiries
    • Subscription Terms of Service
    © 2026 The Smart Investor. All Rights Reserved. The Smart Investor, thesmartinvestor.com.sg, an investment education website managed by The Investing Hustle Pte Ltd (Company Reg No. 201933459Z) is not licensed or otherwise regulated by the Monetary Authority of Singapore, and in particular, is not licensed or regulated to carry on business in providing any financial advisory service. Accordingly, any information provided on this site is meant purely for informational and investor educational purposes and should not be relied upon as financial advice. No information is presented with the intention to induce any reader to buy, sell, or hold a particular investment product or class of investment products. Rather, the information is presented for the purpose and intentions of educating readers on matters relating to financial literacy and investor education. Accordingly, any statement of opinion on this site is wholly generic and not tailored to take into account the personal needs and unique circumstances of any reader. The Smart Investor does not recommend any particular course of action in relation to any investment product or class of investment products. Readers are encouraged to exercise their own judgment and have regard to their own personal needs and circumstances before making any investment decision, and not rely on any statement of opinion that may be found on this site.

    Type above and press Enter to search. Press Esc to cancel.